

EQA round: BIL2/23 - Bilirubin Neonatal

Deadline: 25.8.2023

Setup: groups - manufacturer of kit; minimal size of the groups n = 5

RoM = robust average

SD = standard deviation

CV = coefficient of variation

N_{tot} = total number of the resultsN_{out} = number of the results removed before calculation

AV = assigned value

CVP = consensus of all participants

U_{AV} = expanded uncertainty of the assigned value (k = 2)D_{max} = acceptable difference

LL = lower limit

UL = upper limit

N_{eva} = number of the results assessedN_{suc} = number of successful resultsS_{rel} = relative success

Test Sample Group	[unit]	RoM	SD	CV [%]	N _{tot}	N _{out}	Comparability									
							AV	U _{AV}	D _{max}	LL	UL	N _{eva}	N _{suc}	S _{rel} [%]		
(215) Bilirubin total	[μmol/L]				120							120	115	96		
Sample A		319	20	6,3	120		CVP	319	4,5	18%	261	377	120	115	96	
(1) Abbott		328	16	4,8	20	0							20			
(58) Beckman Coulter (AU)		315	10	3,2	22	0							22			
(60) Roche		305	11	3,6	49	0							49			
(162) Siemens (Atellica)		358	21	6	9	0							9			
(179) Siemens		354	34	9,6	7	0							7			
Other					13	0							13			
								1x 12, 1x 40, 2x 46, 1x 61, 1x 70, 1x 77, 3x 149, 1x 158, 2x 178								
Sample B		208	14	6,8	120		CVP	208	3,1	18%	170	246	120	118	98	
(1) Abbott		214	16	7,3	20	0							20			
(58) Beckman Coulter (AU)		206	9,6	4,7	22	0							22			
(60) Roche		198	6,8	3,4	49	0							49			
(162) Siemens (Atellica)		233	15	6,5	9	0							9			
(179) Siemens		236	5,2	2,2	7	0							7			
Other					13	0							13			
								1x 12, 1x 40, 2x 46, 1x 61, 1x 70, 1x 77, 3x 149, 1x 158, 2x 178								